OBJECTIVE: To explore the expression of oncogene C-erbB2 in breast cancer, its relationship to estrogen receptor (ER), progesterone receptor (PR) and PS2 and the prognostic significance. METHODS: The expression of oncogene C-erbB2 in 245 cases with breast cancer was detected with immunohistochemical technique (LsAB). RESULTS: Expression of oncogene C-erbB2 was found in 60% cases of breast cancer. Tumors positive for C-erbB2 were 45.19% and 71.55% in ER positive group and ER negative group respectively, while tumors positive for C-erbB2 were 48.08% and 70.43% in PR positive group and PR negative group respectively. The expression of the C-erbB2 was 23.26% in group of PS2 positive and 50.75% in group of PS2 negative (P < 0.05). No significant association of C-erbB2 expression with age and tumor size was noted(P > 0.05), but its expression in breast cancer was correlated with advanced clinical stage, high histological grade, axillary lymph node involvement (P < 0.05). CONCLUSION: C-erbB2 would be helpful to the evaluation of prognosis and treatment in breast cancer.
OBJECTIVE: To explore the expression of oncogene C-erbB2 in breast cancer, its relationship to estrogen receptor (ER), progesterone receptor (PR) and PS2 and the prognostic significance. METHODS: The expression of oncogene C-erbB2 in 245 cases with breast cancer was detected with immunohistochemical technique (LsAB). RESULTS: Expression of oncogene C-erbB2 was found in 60% cases of breast cancer. Tumors positive for C-erbB2 were 45.19% and 71.55% in ER positive group and ER negative group respectively, while tumors positive for C-erbB2 were 48.08% and 70.43% in PR positive group and PR negative group respectively. The expression of the C-erbB2 was 23.26% in group of PS2 positive and 50.75% in group of PS2 negative (P < 0.05). No significant association of C-erbB2 expression with age and tumor size was noted(P > 0.05), but its expression in breast cancer was correlated with advanced clinical stage, high histological grade, axillary lymph node involvement (P < 0.05). CONCLUSION:C-erbB2 would be helpful to the evaluation of prognosis and treatment in breast cancer.